Bispecific antibody · Immune activation, directed at OX40 (TNFRSF4) and CD137 (4-1BB) (TNFRSF9)
Phase 1Most advanced trial (none active)
What is FS120?
FS120 is a tetravalent IgG1 bispecific antibody that simultaneously binds and activates the co-stimulatory receptors OX40 and CD137 on T-lymphocytes and natural killer cells. It is being studied in advanced and metastatic cancer, including in combination with pembrolizumab.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Pembrolizumab (KEYTRUDA)
Drug type
Bispecific antibody
Targets
OX40 (TNFRSF4), CD137 (4-1BB) (TNFRSF9)
Mechanism
Immune activation, directed at OX40 (TNFRSF4) and CD137 (4-1BB) (TNFRSF9)
Pathways
T-cell co-stimulation, T-cell proliferation and survival, NK cell activation
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.